Advanced searches left 3/3

Carbon-13 - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 August 2022

* If you want to update the article please login/register

Single Institution Feasibility Study to Detect Radiation-Induced Cardiotoxicity in Receiving Thoracic Radiation Patients Using Hyperpolarized Carbon 13-Based Magnetic Resonance Spectroscopic Imaging

With an incidence of 17. 5 million cancer cases worldwide, the global burden of cancer continues to rise. Approximately 50% of all cancer patients receive radiation therapy as a component of their cancer treatment. Although radiation therapy has shown to be helpful in patients with many forms of cancer, many forms of malignancies have been diagnosed, patients with chest radiotherapy have a significant concern. The researchers will recruit five female patients with left-sided breast cancer who underwent lumpectomy or mastectomy without tissue expander placement, and radiation-induced heart disease in such patients is now a common cause of morbidity and mortality in those patients. Following breast radiotherapy, strain rate imaging by MRI has been shown in previous studies that it is a sensitive method for dose-dependent reduction in myocardial function. Women should not become pregnant nor menstruate, while men should not father a baby while participating in this study because we don't know how the study findings/prophedures may influence a man's sperm or a fetus if a woman becomes pregnant during the investigation. If you suspect you have become pregnant or if your female partner has become pregnant while you are in this study, you should notify one of the study's researchers right away so that the pregnancy management and the possibility of stopping the research can be discussed.

Source link: https://clinicaltrials.gov/ct2/show/NCT04044872


Hyperpolarized 13C Pyruvate Metabolic MRI to Predict Renal Tumor Aggressiveness

OBJECTIVES OF THE SECONDARY: Objectives: To determine the reproducibility of HP 13C pyruvate MRI in patients undergoing an optional second HP 13C pyruvate MRI. To determine the efficacy of HP 13C pyruvate in renal tumor patients, a new study was conducted. OUTLINE: Patients receive HP 13C pyruvate intravenously and then undergo a 13C MRI scan 1-2 minutes after HP 13C pyruvate injection, with the exception of HP 13C pyruvate injection. Patients can be branded again with an optional HP 13C pyruvate injection and under a 13C pyruvate MRI scan 15 to 60 minutes after the first scan's completion.

Source link: https://clinicaltrials.gov/ct2/show/NCT04258462


Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Diagnostic and Response Monitoring Imaging Tool in Advanced Prostate Cancer

According to Prostate Cancer Working Group 3 guidelines, determining if the change from baseline in kPL and kPG is associated with subsequent clinical findings on treatment, including prostate specific antigen response rate and radiographic progression-survival. Respondent Response Criteria in Solid Tumors 1. 1 criteria will determine whether baseline and/or change from baseline in intratumoral kPL and kPG is related to subsequent objective response by RECIST criteria. To investigate for connection between HP kPL and kPG, as well as areas under the curve lac/pyr and pyr ratios, with tissue-based indicators of elevated lactate and glutamate metabolism, including MYC and PDH protein expression. Patients are treated with C-1-labelled hyperpolarized carbon C 13 pyruvate intravenously for less than 1 minute, followed by magnetic resonance spectroscopic imaging in less than 5 minutes. Following the first scan, patients may also be given an optional C-2 labeled hyperpolarized carbon C 13 pyruvate IV and MRSI within 15-60 minutes. Patients receive C-1 labeled hyperpolarized carbon C13 pyruvate IV over less than a minute, then undergo MRSI for less than 5 minutes. Patients may also be able to receive an optional C-13 labeled hyperpolarized carbon C 13 pyruvate IV and MRSI within 15-60 minutes after completion of the first scan at baseline and 12 weeks.

Source link: https://clinicaltrials.gov/ct2/show/NCT04346225

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions